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Background: Vaccination is considered as the most effective preventive method to control influenza. The hallmark
of influenza virus is the remarkable variability of its major surface glycoproteins, HA and NA, which allows the virus
to evade existing anti-influenza immunity in the target population. So it is necessary to develop a novel vaccine to
control animal influenza virus. Also we know that the ectodomain of influenza matrix protein 2 (M2e) is highly
conserved in animal influenza A viruses, so a vaccine based on the M2e could avoid several drawbacks of the
traditional vaccines. In this study we designed a novel tetra-branched multiple antigenic peptide (MAP) based
vaccine, which was constructed by fusing four copies of M2e to one copy of foreign T helper (Th) cell epitope, and
then investigated its immune responses.
Results: Our results show that the M2e-MAP induced strong M2e-specific IgG antibody,which responses following
2 doses immunization in the presence of Freunds’ adjuvant. M2e-MAP vaccination limited viral replication
substantially. Also it could attenuate histopathological damage in the lungs of challenged mice and counteracted
weight loss. M2e-MAP-based vaccine protected immunized mice against the lethal challenge with PR8 virus.
Conclusions: Based on these findings, M2e-MAP-based vaccine seemed to provide useful information for the
research of M2e-based influenza vaccine. Also it show huge potential to study vaccines for other similarly viruses.
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Influenza virus is a globally important respiratory pathogen
which causes a high degree of morbidity and mortality in
humans and animals annually [1]. Influenza virus typically
infects 10~20% of the total worldwide population during
seasonal epidemics, resulting in three to five million cases
of severe illness and 250,000 to 500,000 deaths per year [2].
Moreover, novel influenza strains appear occasionally in
the human population, causing pandemics. In 2009, the
world confronted the first influenza pandemic of the 21st
century, which iscaused by a novel influenza A H1N1 virus
[3]. Antigenic and genetic analysis has suggested that this
pandemic H1N1 virus is a product of reassortment
between genes of the human, avian and swine influenza
strains [4].* Correspondence: gztong@shvri.ac.cn
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reproduction in any medium, provided the orTo date, vaccination is considered as the most effective
preventive measure to control influenza. However,
conventional vaccines have many drawbacks, the most
important is the uncertainty of virus selection strains to
be included in each year’s vaccine formulation [5]. The
hallmark of influenza virus is the remarkable variability of
its major surface glycoproteins, HA and NA, which allows
the virus to evade existing anti-influenza immunity in the
target population [6]. The potential shortage of pandemic
influenza vaccines and the absence of specific-immunity
in the human population make the development of a
cross-protective influenza vaccine, which is based on
conserved antigens, a promising prophylactic strategy.
M2e, the ectodomain of the M2 protein, is highly
conserved across influenza a subtypes and has become an
attractive antigen target for producing a cross-protective
influenza vaccine conferring broad spectrum prevention
[7-9]. In contrast to BALB/c mice, Wolf AI, et al. show
that immunization of other inbred and outbred mouse. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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it correlated with a defect in T cell but not B cell respon-
siveness to the M2e-MAPs [10].
In this study we designed a novel tetra-branched mul-
tiple antigenic peptide (MAP) based vaccine, which was
constructed by fusing four copies of M2e to one copy of
foreign T helper (Th) cell epitope. The vaccine can provide
heterosubtypic protection against lethal virus challenge.
Results
M2e-MAP immunization could induce high titers of
M2e-specific IgG antibodies
To evaluate humoral immune responses induced by M2e-
MAP, mice were vaccinated with 10 μg of M2e-MAP plus
Freund’s adjuvant as described in Methods, and M2e-
specific IgG antibodies were detected in mouse serum
samples by ELISA. As shown in Figure 1, M2e-MAP
induced strong M2e-specific IgG antibody responses, with
the titer of 1:103 7 days post first immunization, then
the titer reached of 1:104 before boost, and increased to
the highest titer over 1:105 14 days post the boost
immunization. In contrast, only background level of
antibody responses was detected in the mice vaccine
with Freund’s adjuvant alone.
M2e-MAP vaccination limited replication of virus and
attenuated virus-induced lung pathology
Two weeks post boost immunization, mice were challenged
with a lethal dose (10LD50) of PR8 and 10





























Figure 1 M2e-specific antibody titers induced by M2e-MAP
vaccine. Mice were vaccinated with M2e-MAP plus Freund adjuvant
(s. c.). Mice receiving Freund were used as negative controls. Sera
were collected at 1, 2, 3, 4 weeks post first immunization. The titers
were expressed as the highest serum dilution which is greater than
twice the average absorbance value at OD450 nm of pre-vaccination
sera. The data are expressed as geometric mean titer (GMT) ±
standard deviation (SD) of 10 mice per group. The lower limit
detection (1:20) is indicated by a dotted line. Experiments were
repeated three times.SwGD96 and SwHLJ1. The vaccinated mice were sacrificed
three days after challenge and lung tissues were collected
for the detection of viral titers and histopathological
examination. Viral titers were determined in SPF eggs and
real time PCR methods [11]. In the control group, 3 differ-
ent types of virus replicated to titers from 102.15 to 105.80
EID50/ml in lungs. In contrast, in SwHLJ1 and SwGD96
challenged group, virus cannot detect in lungs of mice
immunized with M2e-MAP (<1.0 log10 EID50/ml) and
the titer in lungs dropped to 103.60 EID50/ml in PR8
challenged mice(Table 1).Compared with the adjuvant
control group, the average viral amounts in lungs of M2e-
MAP-vaccinated mice was significantly lower (P < 0.001)
after challenge with SwHLJ1, SwGD96 and PR8 viruses
(Figure 2), which suggested that the M2e-MAP can induce
potent protective immunity against viral replication fol-
lowing infection with different types of influenza A virus.
Histopathologic examination showed that PR8 challenged
mice, adjuvant control group revealed dramatic histo-
pathological damages including large inflammatory cell
infiltration, lung tissue necrosis, abscess formation and
accompanied by bleeding, and some lungs tissue showed
compensatory emphysema (Figure 3D). In contrast, the
M2e-MAP-vaccinated mice lungs exhibited relatively
minor pathological changes, with only slight expansion of
alveoli, and the interval of alveolar became slightly flat
because of pressure (Figure 3A). The vaccine also protected
mice against infection by SwHLJ1 and SwGD96 virus,
the M2e-MAP-vaccinated mice showed no obvious
pathological damage (Figure 3B and C). On the contrary,
the adjuvant control mice appeared interstitial pneumonia,
alveolar capillaries and small blood vessel wall dilatation
and congestion, accompanied by a small amount of bleed-
ing (Figure 3E and F). The above data suggested that
M2e-MAP vaccination may protect the mice against
challenge of SwHLJ1, SwGD96 and PR8 virus through a
combination of limiting viral replication in the lungs and
attenuating virus-induced lung pathology.
M2e-MAP vaccination provided effective protection from
lethal challenge with PR8 virus
To further confirm the protective immunity of M2e-MAP
vaccination against lethal infection, mice received lethal
challenge (10LD50) of A/Puerto Rico/8/34(PR8; H1N1)
strain were monitored for weight loss and death for
the subsequent two weeks postchallenge. As shown in
Figure 4B, mice vaccinated with M2e-MAP in Freund’s
adjuvant rallied from body weight loss eight days after
virus infection. In contrast, body weight of the mice in the
adjuvant control group dramatically decreased, almost
30%, in some cases. All mice received adjuvant alone died
within 9 days after lethal virus challenge. In comparison,
100% of the mice survived in the groups vaccinated with
M2e-MAP, with the survival rate significantly different
Table 1 Virus isolation and titrations in lungs on day 3 post challenge
Immunogena Virus isolation/total Protection against challenge and virus titerb
(log10 EID50/ml±S.D.)
PR8 SwGD96 SwHLJ1 PR8 SwGD96 SwHLJ1
M2e-MAP+Freund 5/5 0/5 0/5 3.60±0.22 <1 <1
Freund 5/5 5/5 5/5 5.80±0.27 3.26±0.29 2.15±0.34
a. 60 mice per group were injected twice subcutaneously with M2e-MAP plus Freund and Freund as control.
b. Mice were challenged intranasally 2 weeks post 1st boost with 106EID50 of SwGD96, SwHLJ1 and 10LD50 of PR8 viruses. Virus titer of lungs was determined 3
days later in ECE. The values were calculated by the method of Reed-Muench and expressed as the mean log10 EID50/ml±S.D. The lower limit of detection of
virus was 1.0 log10 EID50/ml.
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These data illustrated that M2e-MAP could afford protec-
tion against lethal challenge of PR8 virus.
Discussion
The considerable antigenic variation in influenza A virus
and other virus such as FMDV and HIV presents problems
in their control by vaccination [12]. In previous researches
anti-M2e Abs induced by M2e-MAPs shows highly cross-
reactive and can mediate protection to various viruses [10].
In the case of influenza A virus, an attractive alternative
approach would be to develop a cross-protective influenza
vaccine based on conserved antigens such as M2e. Several
studies have shown that immunization with M2e can
protect against influenza A virus infection [13]. Different
results and conclusions from previous studies may be due



























Figure 2 Viral amounts in lungs on day 3 post challenge. 5
mice of every challenge group were euthanized 3 days post-
challenge and the viral amounts of lungs were determined by real
time PCR. The values were expressed as the mean log10 viral
copies/μL ±S.D of 5 mice per challenge group. *means in PR8
challenged group P < 0.001 compared to the Freund’s adjuvant
control; **means in SwGD96 challenged group P < 0.001 compared
to the Freund adjuvant control; ***indicates in SwHLJ1 challenged
group P < 0.001 compared to the Freund adjuvant control.of administration. The vaccine described in the present
study has several advantages. The researchers showed
that branched MAP based vaccine is better than single
peptide based vaccine, and results also demonstrated
that MAP-based vaccine could give high-titer antibody
responses [8]. And vaccines with T-helper epitope can
induce an antibody response [14]. So we have designed
the vaccine by fusing four copies of M2e to one copy of
foreign T helper (Th) cell epitope.
In this study, virus titers were determined by two
methods, the first one is the traditional way by SPF eggs,
and the second method was real time PCR which was
showed previously [11]. Bothexperiments showed that the
M2e-MAP could induce strong M2e-specific IgG anti-
body, which responses following 2 doses immunization in
the presence of Freund and limited viral replication.
Also it could attenuate histopathological damage in the
challenged mice lungs and was able to counteract
weight loss and protect mice from lethal challenge with
PR8 virus. Therefore, the induction of M2e-specific anti-
body responses was necessary for M2e-based vaccines in
the prevention of these three virus infection.
Several distinct M2-based vaccine constructs have been
developed and found that they could induce significant
resistance to influenza type A virus replication in mice
[15-19]. We routinely used a fairly severe viral challenge
to evaluate the efficacy of the M2e-based vaccination. It
may be noted that the challenge conditions used by
various viruses to score protection after vaccination
with an M2e-based vaccine vary widely [20-22]. In this
study high titers M2e-specific antibody responses could
be induced following immunization of M2e-MAP plus
Freunds’ adjuvant. Using three virus strains to challenge
the immuned mice and got good results. After challenged
by PR8 virus, a highly lethal virus, it demonstrated a clear-
cut protection against mortality. The rest two mild virulence
virus strains did not allow to score for survival, but the
protection was assayed by reduction of virus titer in lungs
homogenates. So we can know that the M2e-MAP play
important role in the development of the vaccine.
In conclusion, we designed a novel tetra-branched
multiple antigenic peptide (MAP) based vaccine, which
was constructed by fusing four copies of M2e to one
Figure 3 Histopathological changes in the lungs of virus challenged mice. Immunized mice were challenged by PR8 (A and D), SwGD96
(B and E) and SwHLJ1(C and F) and lungs were collected for histopathological analysis 3 days post challenge (HE stain; bar = 50 um).The figure
indicates the representative imagines of histopathological observations of M2e-MAP plus Freund immunized mice or Freund only.
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provided useful information for the further development
of M2e-based influenza vaccine.Materials and methods
Virus and peptide
A/Swine/Heilongjiang/1/05(SwHLJ1; H3N2), A/Swine/
Guangdong/96/06(SwGD96; H1N1)were isolated from
China [23,24]. A/Puerto Rico/8/34(PR8; H1N1) is a
mouse-adapted virus. Viruses were grown in allantoic
fluids of 10-day-old SPF embryonated chicken eggs at
37°C for 3 days. Virus were harvested and stored in
aliquots at −80°C. The 50% lethal dose (LD50) of PR8 was
determined in mice after serial dilutions of the virus stock
and the result was calculated by Reed Muenchmethod
[25]. The tetra-branched M2e-MAP was constructed by
fusing four copies of a universal sequence which is an
extracellular part of M2 protein with one copy of promis-
cuous T helper (Th) cell epitope [26] by a lysine tree with
two additional Lys residues defining a putative cleavage
site for cathepsin D [27]. Then it was synthesized by
Genscript Co., Ltd (China). The synthesized peptide
was prepared at 10 mg/mL in distilled water and stored
at −20°C.The structure of M2e-MAP is shown in Figure 5.Immunization and virus challenge
Six to eight weeks old female SPF BALB/c mice were pur-
chased from the Sino-British SIPPR/BK Animal Co., Ltd
(Shanghai, China) and were immunized subcutaneously
(s. c.) with M2e-MAP (10μg per mouse) plus Freund’s
complete adjuvant (FCA, sigma) at a final volume of 100
μL and boosted with the same amount of immuogen in
Freund’s incomplete adjuvant (FIA, Sigma) at a 2-week
intervals. Mice injected with Freund’s adjuvant alone were
used as negative control. Mice sera were collected at
0,1,2,3 and 4 weeks post first immunization to detect
specific antibody responses.
Two weeks after boost, mice were anesthetized and
challenged intranasally (i.n.) with a lethal dose (10LD50) of
PR8 and 106EID50 of SwGD96 and SwHLJ1. Challenged
mice were observed for illness or death and weighed daily
for 2 weeks. Lung tissues were collected from euthanized
mice on day 3 post-challenge for further virological tests
and histopathological analysis.Antibody detection
The M2e-specific antibody titers were determined by end-
point ELISA. Briefly, 96-well microtitre plates (Costar)
were coated with peptide (0.5 μg per well) in 0.1 M
Survival curve











































Figure 4 Survival curve and body weight in PR8 challenged
mice. Survival curve and body weight in PR8 challenged mice. Mice
were challenged with 10LD50 of PR8 virus intranasally and
monitored daily for 2 weeks post challenge. A. Survival rate. The
significant different (P<0.0001) of M2e-MAP+Freund versus Freund
alone is indicated as *. B. Percentage (%) of mouse body weight.
Each point represents mean of 10 mice per group.
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with 5% skim milk in PBS for 2 h, serial diluted mice sera
samples were added and incubated for 1 h at 37°C.
Washing the ELISA plate, andhorseradish peroxidase
(HRP)-labeled goat anti-rabbit IgG (1:10,000 dilution,
Beijing Zhongshan Biotechnology) was added and incu-
bated for 1 h at 37°C. Assay was developed using 3, 3′, 5,
5′-tetramethylbenzidine (TMB) (Amresco), and the
reaction was stopped by adding 2 M H2SO4. TheFigure 5 Structure of the synthetic M2e-MAP. The M2e-MAP was synth
tetra-branched form, which carries four copies of M2e, those four copies ofabsorbance at 450 nm was measured by microplate
autoreader (BioTek Instruments). The reciprocal of the
highest dilution of the serum that is greater than twice
average absorbance value of pre-vaccination serum was
designated as the antibody titer.Virus titers in lung
Lung tissues from euthanized mice were aseptically
removed and homogenized in 1 ml of cold PBS. The
homogenates were frozen at −80°C and later thawed for
ease of handing. Solid debris was pelleted by centrifugation.
Serial diluted from initial dilutions of 1:10 and then titrated
for virus infectivity in 10-day-old SPF ECE. Virus titers were
calculated by the Reed-Muench method and expressed as
mean log10EID50 per milliliter ± standard deviation (SD).
In addition, lung tissues were also collected and tested
by real-time RT-PCR assay recommended by WHO with
some modifications as described [11]. Lung tissues were
homogenized in 300 μL of cold PBS and viral RNA were
extracted by RNeasy Plus Mini kit (QIAGEN). Then
reverse transcription were performed and viral amounts
in lungs were determined by real-time PCR using the InfA
primers and TaqMan probe. The specific primers and




The lung tissues of challenged mice were removed and
immediately fixed in 10% neutral buffered formalin, and
then embedded in paraffin wax. Sections were made at
4–6 μm thickness and mounted on slides. Histopatho-
logical changes were examined by H & E staining and
observed under light microscopy.esized on [Fmoc-Lys (Fmoc)] 2-Lys-Cys (Acm)-βAla-Wang Resin in a
M2e were fused to one copy of foreign T helper (Th) cell epitope.
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The survival curves were calculated by Kaplan-Meier
method and the significance were analyzed with log-rank
test. Other data were analyzed by two-tailed Student’s t
test. P < 0.0001 was considered significantly different. All
analysis were performed by Graphpad Prism software.
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